Product Name :
LAG-3 (human) recombinant monoclonal antibody (L4-PL33)
Sequence:
Purity:
Molecular Weight:
Solubility :
Appearance:
Use/Stability :
Stable for at least 6 months after receipt when stored as recommended.
Description:
The lymphocyte activation gene-3 (LAG-3, CD223), a member of the immunoglobulin superfamily (IgSF) related to CD4, binds to the major histocompatibility complex (MHC) class II molecules but with higher affinity than CD4. Several alternative mRNA splice-variants of human LAG-3 have been described, two of them encoding potential secreted forms: LAG-3V1 (i.{{1217457-86-7} medchemexpress|{1217457-86-7} Purity & Documentation|{1217457-86-7} Purity|{1217457-86-7} supplier} e. the D1-D2 domains of the protein, 36 kDa) and LAG-3V3 (D1-D3, 52 kDa). The longer form was detected by ELISA in the serum of healthy individuals as well as of tuberculosis patients with a favorable outcome. LAG-3 expression by T cell clones correlated with IFN-γ production, and hence soluble LAG-3 has been suggested as a serological marker of Th1 responses. Figure 1: Immunohistochemistry analysis of human tonsil tissue (20x) using LAG-3 (human) recombinant mAb (L4-PL33), , at a dilution of 1:50. Figure 2: Immunohistochemistry analysis of human tonsil tissue (60x) using LAG-3 (human) recombinant mAb (L4-PL33), , at a dilution of 1:50 IHC performed on human tonsil tissue using LAG-3 (human) recombinant mAb (L4-PL33) , at a dilution of 1:50. Western blot analysis of LAG-3 recombinant mAb (L4-PL33) using different cell lysates and purified LAG-3 protein: Lane 1 and 2: MW markers, Lane 3: Jurkat, Lane 4: HeLa, Lane 5: Empty, Lane 6: THP-2, Lane 7: HDML2, Lane 8: Empty, Lane 9: LAG-3 (human):Fc (human), (recombinant) . Figure 1: Immunohistochemistry analysis of human tonsil tissue (20x) using LAG-3 (human) recombinant mAb (L4-PL33), , at a dilution of 1:50. Figure 2: Immunohistochemistry analysis of human tonsil tissue (60x) using LAG-3 (human) recombinant mAb (L4-PL33), , at a dilution of 1:50 IHC performed on human tonsil tissue using LAG-3 (human) recombinant mAb (L4-PL33) , at a dilution of 1:50. Western blot analysis of LAG-3 recombinant mAb (L4-PL33) using different cell lysates and purified LAG-3 protein: Lane 1 and 2: MW markers, Lane 3: Jurkat, Lane 4: HeLa, Lane 5: Empty, Lane 6: THP-2, Lane 7: HDML2, Lane 8: Empty, Lane 9: LAG-3 (human):Fc (human), (recombinant) .{{915810-67-2} site|{915810-67-2} Protocol|{915810-67-2} In Vivo|{915810-67-2} supplier}
CAS :
Solubility:
Formula:
Additional Information :
| Alternative Name Lymphocyte activation gene-3, FDC protein, CD223 | Application ELISA, Flow Cytometry, ICC, IHC, IP, WB | Clone L4-PL33 | Formulation Liquid.PMID:30969608 In PBS containing 10% glycerol and 0.02% sodium azide. | Host Mouse | Immunogen Synthetic peptide corresponding to 30 aa (GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-terminal D1 domain of human LAG-3 (lymphocyte activation gene-3). | Isotype IgG1κ | Recommendation Dilutions/Conditions Immunohistochemistry (frozen sections, 1:150)Western Blot (5 µg/ml)Immunoprecipitation (10 µg/ml)Suggested dilutions/conditions may not be available for all applications.Optimal conditions must be determined individually for each application. | Source Purified from tissue culture supernatant. | Species Reactivity Human | Specificity Recognizes the 30 aa extra-loop of the first N-terminal D1 domain of LAG-3. | UniProt ID P18627 | Unit of Measure (UM) µg